Assertio Therapeutics (ASRT) Misses Q1 EPS by 9c
Tweet
Share
E-mailGet Alerts ASRT Hot Sheet
Join SI Premium – FREE
Assertio Therapeutics (NASDAQ: ASRT) reported Q1 EPS of ($0.14), $0.09 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $26.49 million versus the consensus estimate of $27.52 million.
For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- Macquarie Upgrades DiDi Global (DIDIY) to Outperform
- JPMorgan Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
